Phase I, Open Label, Dose-escalation Study to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)

Trial Profile

Phase I, Open Label, Dose-escalation Study to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs UCART 19 (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; First in man
  • Acronyms CALM
  • Sponsors Servier
  • Most Recent Events

    • 12 Dec 2017 Preliminary results (n=6; Data cut off: 24 Jun 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Preliminary results presented in a Pfizer media release.
    • 01 Nov 2017 According to a Servier media release, results from this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top